These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37866023)

  • 1. Lessons learned after 20 years of real-world experience with natalizumab.
    Khatri BO; Olapo T; Beals S; Lindman E; Perea T; Van Zealand P; Metzger RR
    Mult Scler Relat Disord; 2023 Dec; 80():105048. PubMed ID: 37866023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world.
    Dsilva L; McCarthy K; Lyons J; Cabigas B; Campbell N; Kong G; Adams B; Kuhelj R; Singhal P; Smirnakis K
    Expert Opin Drug Saf; 2023; 22(10):995-1002. PubMed ID: 37272350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended interval dosing of natalizumab in multiple sclerosis.
    Zhovtis Ryerson L; Frohman TC; Foley J; Kister I; Weinstock-Guttman B; Tornatore C; Pandey K; Donnelly S; Pawate S; Bomprezzi R; Smith D; Kolb C; Qureshi S; Okuda D; Kalina J; Rimler Z; Green R; Monson N; Hoyt T; Bradshaw M; Fallon J; Chamot E; Bucello M; Beh S; Cutter G; Major E; Herbert J; Frohman EM
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):885-9. PubMed ID: 26917698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
    Ryerson LZ; Foley J; Chang I; Kister I; Cutter G; Metzger RR; Goldberg JD; Li X; Riddle E; Smirnakis K; Kasliwal R; Ren Z; Hotermans C; Ho PR; Campbell N
    Neurology; 2019 Oct; 93(15):e1452-e1462. PubMed ID: 31515290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
    J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of natalizumab extended interval dosing.
    Yamout BI; Sahraian MA; Ayoubi NE; Tamim H; Nicolas J; Khoury SJ; Zeineddine MM
    Mult Scler Relat Disord; 2018 Aug; 24():113-116. PubMed ID: 29982107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.
    Rabea EM; Belal MM; Hafez AH; Elbanna AH; Khalifa MA; Nourelden AZ; Mahmoud NH; Zaazouee MS
    Acta Neurol Belg; 2024 Apr; 124(2):407-417. PubMed ID: 38457005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
    Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J
    Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
    Scarpazza C; De Rossi N; Tabiadon G; Turrini MV; Gerevini S; Capra R
    Neurol Sci; 2019 Oct; 40(10):2119-2124. PubMed ID: 31175467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
    Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
    Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
    PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis.
    Mathew T; Kamath V; John SK; Netravathi M; Iyer RB; Raghavendra S; Kumar S; Neeharika ML; Gupta S; Murgod U; Shivakumar R; Annadure RK; Ichaporia N; Rohatgi A; Nair SS; Yareeda S; Anand B; Singh P; Renukaradhya U; Arulselvan V; Reddy YM; Surya N; Sarma GRK; Nadig R; Deepalam S; Sharath Kumar GG; Satishchandra P; Singhal BS; Parry G
    Mult Scler Relat Disord; 2022 Oct; 66():104059. PubMed ID: 35908446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    Chisari CG; Comi G; Filippi M; Paolicelli D; Iaffaldano P; Zaffaroni M; Brescia Morra V; Cocco E; Marfia GA; Grimaldi LM; Inglese M; Bonavita S; Lugaresi A; Salemi G; De Luca G; Cottone S; Conte A; Sola P; Aguglia U; Maniscalco GT; Gasperini C; Ferrò MT; Pesci I; Amato MP; Rovaris M; Solaro C; Lus G; Maimone D; Bergamaschi R; Granella F; Di Sapio A; Bertolotto A; Totaro R; Vianello M; Cavalla P; Bellantonio P; Lepore V; Patti F;
    J Neurol; 2022 Feb; 269(2):933-944. PubMed ID: 34181077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X
    Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of natalizumab-associated PML with filgrastim.
    Stefoski D; Balabanov R; Waheed R; Ko M; Koralnik IJ; Sierra Morales F
    Ann Clin Transl Neurol; 2019 May; 6(5):923-931. PubMed ID: 31139690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
    Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.